Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02747316
Other study ID # PIANO
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2016
Est. completion date September 2020

Study information

Verified date April 2021
Source Swiss Federal Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Overweight and obesity causes low-grade systemic inflammation, which sharply increases risk for iron deficiency. Studies in our laboratory have shown that this is mainly the result of reduced dietary iron absorption because of increased hepcidin concentrations. During pregnancy, women have a large increase in iron needs because of the expansion of maternal blood volume and fetal needs. Iron deficiency anemia in infancy can impair cognitive development. Whether maternal adiposity impairs absorption and transfer of iron to the fetus, and thereby increases risk of iron deficiency in the mother and the infant is unclear.


Description:

In obese subjects, hepcidin concentrations are increased and iron absorption is believed to be reduced, leading to iron deficiency over time. How all this will influence iron supply of the fetus in obese pregnancy has not been well investigated to date. Even if maternal and fetal iron uptakes are regulated separately, it is unclear to what extent maternal subclinical inflammation might influence this process. A small study by Dao et al. indicated that maternal-fetal iron transfer was impaired in obese pregnant women, possibly due to hepcidin up-regulation. In this study, both maternal BMI as well as hepcidin were negatively correlated with cord blood iron status. Maternal hepcidin and c-reactive protein were significantly higher and cord blood iron was significantly lower in the obese compared to the normal weight. Hepcidin was shown to have an effect on iron transfer across the placenta in the study by Young et al.: the transfer was increased in women with undetectable hepcidin at delivery compared to those with higher levels. As of now, clear associations between maternal BMI or maternal hepcidin concentration and fetal iron status were not shown.


Recruitment information / eligibility

Status Completed
Enrollment 83
Est. completion date September 2020
Est. primary completion date April 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Pregnant women with either normal pre-pregnancy BMI (BMI 18.5 - 24.9kg/kg2) or with overweight or obesity (BMI > 27.5kg/m2) before pregnancy (assessed based on data reported by the women at their first visit at the hospital) - 18 to 45 years old - singleton pregnancy - week of pregnancy 14±3 Exclusion Criteria: - underlying malabsorption disease - chronic illness, which influences iron absorption - inflammatory status other than obesity - medical problems known to affect iron homeostasis - smoking during pregnancy - no regular use of medication, which influences iron absorption

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Stable iron isotope 57 (57Fe) labeled iron solution
test meal labeled with 12 mg 57Fe
Stable iron isotope 58 (58Fe) labeled iron solution
test meal labeled with 12 mg 58Fe

Locations

Country Name City State
Switzerland Human Nutrition Laboratory ETH Zurich Zurich

Sponsors (1)

Lead Sponsor Collaborator
Swiss Federal Institute of Technology

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fractional iron absorption The fractional iron absorption from the first test meal will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meal. week 20 of pregnancy
Primary iron transfer from the mother to the fetus in cord blood/infant To determine the amount of iron transferred from the mother to the fetus delivery
Primary Fractional iron absorption The fractional iron absorption from the second test meal will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meal. week 30 of pregnancy
Primary infants iron status infants iron status over the first six months of life
Secondary Change in plasma ferritin Change in plasma ferritin weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Change in Hepcidin Change in Hepcidin weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Change in transferrin receptor Change in transferrin receptor weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Change in hemoglobin Change in hemoglobin weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Change in c-reactive protein Change in c-reactive protein weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Change in interleukin-6 Change in interleukin-6 weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Chage in alpha-1-acid glycoprotein Chage in alpha-1-acid glycoprotein weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Change in retinol binding protein Change in retinol binding protein weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Change in riboflavin Change in riboflavin weeks of pregnancy 12, 18, 20, 28, 30, 36; 3 and 6 months after delivery
Secondary Assessment of children's iron needs within their first 2 years of life using an isotope dilution technique Assessment of children's iron needs within their first 2 years of life Follow-up blood samples at 3, 6, 12, 18, 24 months after birth
Secondary Assessment of recovery of mother's iron Status after pregnancy using an isotope dilution technique Assessment of recovery of mother's iron Status after pregnancy Follow-up blood samples at 3, 6, 12, 18, 24 months after delivery
Secondary infants iron status infants iron status over the first 24 months of life
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2